Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
NCT01888081 · Virogen Biotechnology Inc. · PHASE1/PHASE2 · terminated · last registry update 2016-11-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)” | – | Registry record, Virogen Biotechnology Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EEF2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-09-08Results posted on the registry: National Cancer Institute (NCI), LMB-2 + Fludarabine (NCT00924170)
- 2017-08-04Results posted on the registry: University of Washington, ONTAK + protein expression analysis (NCT00425672)
- 2017-06-20Also stopped (terminated): Barbara Ann Karmanos Cancer Institute, Denileukin Diftitox (Ontak) (NCT01251952)
- 2017-05-18Results posted on the registry: Masonic Cancer Center, University of Minnesota, Rituximab + Interleukin-2 (NCT01181258)
- 2017-04-18Results posted on the registry: Alliance for Clinical Trials in Oncology, denileukin diftitox + rituximab (NCT00460109)
- 2016-12-15Also stopped (withdrawn): University of Miami, denileukin diftitox + cyclophosphamide (NCT00513188)
- 2016-09-29Also stopped (terminated): Loyola University, Ontak (NCT00726037)
- 2016-08-24Results posted on the registry: Loyola University, Ontak (NCT00726037)
- 2016-07-26Also stopped (terminated): Hoffmann-La Roche, RO6927005 + RO6927005 (NCT02317419)
- 2016-04-25Also stopped (withdrawn): AbGenomics B.V Taiwan Branch, Neihulizumab Treatment + Conventional Treatment (NCT02694770)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision